UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of October 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 GSK plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Emma Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
29
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Diana Conrad
b)
Position/status
Chief People Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
5
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
11
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
19
 
 

 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Luke Miels
b)
Position/status
Chief Commercial Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
3
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
76
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
29
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
48
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
62
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.3921
58
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
123
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Iain Whyte
b)
Position/status
PCA of Ms V Whyte (SVP & Company Secretary)
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1,152
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Emma Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
105.836
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Diana Conrad
b)
Position/status
Chief People Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1,233.149
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1,024.598
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
453.008
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dylan Jackson
b)
Position/status
PCA of Sally Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
140.210
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
6,278.135
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
2,616.351
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
2,144.723
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Kate Thomson
b)
Position/status
PCA of Philip Thomson (President, Global Affairs)
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
109.382
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1,279.528
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Tony Wood
b)
Position/status
Chief Scientific Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1,270.306
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£16.4016
1.332
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-09
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Elizabeth McKee Anderson
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
26
 
 

 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Charles Bancroft
b)
Position/status
Senior Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
340
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Hal Barron
b)
Position/status
Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
28
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Anne Beal
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
34
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Harry Dietz
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
32
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Jeannie Lee
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
13
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Vishal Sikka
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$43.7375
99
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
 
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: October 13, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc